Sökresultat - "Pieters, Rob"

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Moorman, Anthony V., Enshaei, Amir, Murdy, Daniel, Joy, Melvin, Boer, Judith M., den Boer, Monique L., Pieters, Rob, de Haas, Valerie, Horstmann, Martin A., Escherich, Gabriele, Johansson, Bertil, Marquart, Hanne V., Schmiegelow, Kjeld, Hancock, Jeremy, Moppett, John, Heyman, Mats

Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Genetics, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för klinisk genetik, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Genetics, Genetic and epigenetic studies of pediatric leukemia, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för klinisk genetik, Genetiska och epigenetiska studier av barnleukemi, Originator

Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?

Stutterheim, Janine^{Aff1, IDs41375024023865_cor1}, van der Waarden, Rachella, de Groot-Kruseman, Hester A.^{Aff1, Aff2}, Sonneveld, Edwin^{Aff1, Aff2}, de Haas, Valérie^{Aff1, Aff2}, Dandis, Rana, van der Schoot, C. Ellen, van der Velden, Vincent H. J., Pieters, Rob^{Aff1, Aff2}

The Prognostic Effect of IKZF1 Deletions in ETV6:: RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Ostergaard, Anna, Enshaei, Amir, Pieters, Rob, Vora, Ajay, Horstmann, Martin A., Escherich, Gabriele, Johansson, Bertil, Heyman, Mats, Schmiegelow, Kjeld, Hoogerbrugge, Peter M., Den Boer, Monique L., Kuiper, Roland P., Moorman, Anthony V., Boer, Judith M., Van Leeuwen, Frank N.

Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Genetics, Genetic and epigenetic studies of pediatric leukemia, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för klinisk genetik, Genetiska och epigenetiska studier av barnleukemi, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Genetics, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för klinisk genetik, Originator

BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response

Alieva, Maria^{Aff1, Aff2, IDs41596024009726_cor1}, Barrera Román, Mario^{Aff1, Aff3}, de Blank, Sam^{Aff1, Aff3}, Petcu, Diana^{Aff1, Aff3}, Zeeman, Amber L.^{Aff1, Aff3}, Dautzenberg, Noël M. M., Cornel, Annelisa M.^{Aff1, Aff4}, van de Ven, Cesca^{Aff1, Aff3}, Pieters, Rob, den Boer, Monique L.^{Aff1, Aff3}, Nierkens, Stefan^{Aff1, Aff4}, Calkoen, Friso G. J., Clevers, Hans^{Aff1, Aff3, Aff5, Aff6}, Kuball, Jürgen^{Aff4, Aff7}, Sebestyén, Zsolt, Wehrens, Ellen J.^{Aff1, Aff3}, Dekkers, Johanna F.^{Aff1, Aff3}, Rios, Anne C.^{Aff1, Aff3, IDs41596024009726_cor2}

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?

Østergaard, Anna, Fiocco, Marta^{Aff1, Aff2, Aff3}, de Groot-Kruseman, Hester^{Aff1, Aff4}, Moorman, Anthony V.^{Aff5, Aff6}, Vora, Ajay^{Aff6, Aff7}, Zimmermann, Martin^{Aff8, Aff9}, Schrappe, Martin^{Aff9, Aff10}, Biondi, Andrea^{Aff11, Aff12}, Escherich, Gabriele^{Aff13, Aff14}, Stary, Jan, Imai, Chihaya^{Aff16, Aff17}, Imamura, Toshihiko^{Aff18, Aff19}, Heyman, Mats^{Aff20, Aff21, Aff22}, Schmiegelow, Kjeld^{Aff23, Aff24}, Pieters, Rob^{Aff1, Aff4, IDs41375024022877_cor15}

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia

Verbeek, Tamara C. A. I., Vrenken, Kirsten S., Arentsen-Peters, Susan T. C. J. M., Castro, Patricia Garrido, van de Ven, Marieke, van Tellingen, Olaf, Pieters, Rob, Stam, Ronald W.^{Aff1, IDs4200302406916w_cor8}

Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia

Westerveld, Aimée S. R.^{Aff1, IDs41408024011227_cor1}, Roesthuis, Pien, van der Pal, Helena J. H., Bresters, Dorine, Bierings, Marc, Loonen, Jacqueline, de Vries, Andrica C. H.^{Aff1, Aff3}, Louwerens, Marloes, Koopman, Maria M. W., van den Heuvel-Eibrink, Marry M., van der Heiden-van der Loo, Margriet, Hoogerbrugge, Peter, Janssens, Geert O.^{Aff1, Aff5}, de Krijger, Ronald R.^{Aff1, Aff5}, Ronckers, Cecile M.^{Aff1, Aff6}, Pieters, Rob, Kremer, Leontien C. M.^{Aff1, Aff7}, Teepen, Jop C.

Dexamethasone/vincristine pulses significantly reduce administered doses of 6MP/MTX during maintenance therapy in childhood acute lymphoblastic leukemia

de Haas, Valérie ^⁎, Slot, Esmee ¹, van den Berg, Laura ¹, Dandis, Rana, de Groot-Kruseman, Hester, Pieters, Rob

IGH rearrangements in Down syndrome acute lymphoblastic leukemia

Michels, Naomi ^{a, b}, Admiraal, Jade ^a, Boeree, Aurélie ^a, Sonneveld, Edwin ^a, Moorman, Anthony V. ^c, Escherich, Gabriele ^{d, e}, Sutton, Rosemary ^{f, g}, Beverloo, H. Berna ^h, Pieters, Rob ^a, Zwaan, C. Michel ^{a, b}, den Boer, Monique L. ^{a, b}, Boer, Judith M. ^{a, ⁎}

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

Brigitha, Leiah J.^{Aff1, Aff2}, Mondelaers, Veerle, Liu, Yiwei, Albertsen, Birgitte K., Zalewska-Szewczyk, Beata, Rizzari, Carmelo^{Aff7, Aff8}, Kotecha, Rishi S.^{Aff9, Aff10, Aff11}, Pieters, Rob, Huitema, Alwin D. R.^{Aff1, Aff12, Aff13}, van der Sluis, Inge M.^{Aff1, IDs11095024036933_cor10}

KMT2A-rearranged acute lymphoblastic leukaemia

Kotecha, Rishi S., Pieters, Rob, Stutterheim, Janine

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

Lopez-Millan, Belén, Rubio-Gayarre, Alba, Vinyoles, Meritxell, Trincado, Juan L., Fraga, Mario F., Fernandez-Fuentes, Narcís, Guerrero-Murillo, Mercedes, Martinez, Alba, Velasco-Hernandez, Talia, Falgàs, Aïda, Panisello, Carla, Valcarcel, Gemma, Sardina, José Luis, López-Martí, Paula, Javierre, Biola M., Del Valle-Pérez, Beatriz, García de Herreros, Antonio, Locatelli, Franco, Pieters, Rob, Bardini, Michela, Cazzaniga, Giovanni, Rodríguez-Manzaneque, Juan Carlos, Hanewald, Thomas, Marschalek, Rolf, Milne, Thomas A., Stam, Ronald W., Tejedor, Juan Ramón, Menendez, Pablo, Bueno, Clara

Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia

Jeha, Sima^{Aff1, IDs12325023026967_cor1}, Goto, Hiroaki, Baruchel, André, Boëlle-Le Corfec, Emmanuelle, Geffriaud-Ricouard, Christine, Pieters, Rob, Shin, Hee Young

Clinical presentation and outcome of invasive mould disease in paediatric patients with acute lymphoblastic leukaemia

Bury, Didi, Parmentier, Corline E.J., Tissing, Wim J.E., Pieters, Rob, Bont, Louis J., Brüggemann, Roger J., Wolfs, Tom F.W.

Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations

Michels, Naomi, Hormann, Femke M., Boeree, Aurélie, Sonneveld, Edwin, Moorman, Anthony V., Escherich, Gabriele, Sutton, Rosemary, Beverloo, H. Berna, Pieters, Rob, Zwaan, C. Michel, den Boer, Monique L., Boer, Judith M.

A joint international consensus statement for measuring quality of survival for patients with childhood cancer

van Kalsbeek, Rebecca J.^{Aff1, IDs4159102302339y_cor1}, Hudson, Melissa M., Mulder, Renée L., Ehrhardt, Matthew, Green, Daniel M., Mulrooney, Daniel A., Hakkert, Jessica, den Hartogh, Jaap, Nijenhuis, Anouk, van Santen, Hanneke M.^{Aff1, Aff4}, Schouten-van Meeteren, Antoinette Y. N., van Tinteren, Harm, Verbruggen, Lisanne C., Conklin, Heather M., Jacola, Lisa M., Webster, Rachel Tillery, Partanen, Marita, Kollen, Wouter J. W., Grootenhuis, Martha A., Pieters, Rob, Kremer, Leontien C. M.^{Aff1, Aff5}

Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib

van der Sluis, Inge M., van Dijk, Nikita D., Brigitha, Leiah J., Steinhauer, Freya M., Pieters, Rob

Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia—results of a double-blind, randomised controlled trial with cross-over design

van Hulst, Annelienke M., van den Akker, Erica L.T., Verwaaijen, Emma J., Fiocco, Marta, Rensen, Niki, van Litsenburg, Raphaële R.L., Pluijm, Saskia M.F., Zwaan, C. Michel, van Santen, Hanneke M., Pieters, Rob, Evers, Andrea W.M., Grootenhuis, Martha A., van den Heuvel-Eibrink, Marry M.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia

Schneider, Pauline, Crump, Nicholas T.^{Aff2, Aff3}, Arentsen-Peters, Susan T.C.J.M., Smith, Alastair L., Hagelaar, Rico^{Aff1, Aff4}, Adriaanse, Fabienne R.S., Bos, Romy S., de Jong, Anja, Nierkens, Stefan, Koopmans, Bianca, Milne, Thomas A., Pieters, Rob, Stam, Ronald W.^{Aff1, IDs40164023004458_cor13}